Literature DB >> 8609521

Development of myasthenia gravis during interferon-alpha treatment for anti-HCV positive chronic hepatitis.

G Mase, M Zorzon, E Biasutti, B Vitrani, G Cazzato, F Urban, M Frezza.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8609521      PMCID: PMC1073867          DOI: 10.1136/jnnp.60.3.348-a

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  1 in total

Review 1.  Acetylcholine receptor and myasthenia gravis.

Authors:  B W Fulpius; A D Zurn; D A Granato; R M Leder
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

  1 in total
  5 in total

1.  STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-alpha in the central nervous system.

Authors:  Jianping Wang; Robert D Schreiber; Iain L Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

2.  Side effects of interferon-alpha therapy.

Authors:  Stefan Sleijfer; Marjolein Bannink; Arthur R Van Gool; Wim H J Kruit; Gerrit Stoter
Journal:  Pharm World Sci       Date:  2005-12

Review 3.  Cytokine-induced autoimmune disorders.

Authors:  P Miossec
Journal:  Drug Saf       Date:  1997-08       Impact factor: 5.606

4.  Myasthenia gravis: another autoimmune disease associated with hepatitis C virus infection.

Authors:  S Eddy; R Wim; V E Peter; R Tanja; T Jan; V S Werner
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

5.  Myasthenia Crisis Induced by Pegylated-Interferon in Patient With Chronic Hepatitis C: A Case Report.

Authors:  Su Jung Baik; Tae Hun Kim; Hye In Kim; Jeong Yeon Rhie
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.